Jefferies keeps EUR 55.00 target for Fresenius stock
Published on 10/14/2026 at 14:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Jefferies maintained its EUR 55.00 target and Buy rating for Fresenius on October 5, 2026.
- Revenue rose 6.00 percent in second-quarter 2026.
- Fresenius stock costs EUR 43.21 at Lang & Schwarz on October 14, 2026 at 2:01 p.m. CEST, 0.96 percent above the Xetra close of October 13, 2026.
- The price-to-earnings ratio is 15.70 and the next reporting date is November 4, 2026.
Jefferies maintained a Buy rating and a EUR 55.00 price target for Fresenius on October 5, 2026, according to wallstreetONLINE. Against the EUR 43.21 Lang & Schwarz price on October 14, 2026, the target stands 27.29 percent higher. Fresenius stock was trading at EUR 43.21 at Lang & Schwarz at 2:01 p.m. CEST, 0.96 percent above the Xetra close of EUR 42.80 on October 13, 2026.
Second-quarter revenue rose 6.00 percent
Fresenius reported group revenue of EUR 5.864 billion for the second quarter of 2026, up 6.00 percent from EUR 5.571 billion in the second quarter of 2025, according to its investor-relations overview. Core net income reached EUR 470 million, up 14.00 percent from EUR 412 million in the same prior-year period, while core earnings per share rose to EUR 0.83 from EUR 0.73.
The operating mix also moved higher in the reported quarter. Kabi revenue reached EUR 2.244 billion, up 7.00 percent year over year, and Helios revenue was EUR 3.526 billion, up 5.00 percent.
Stock sits 18.41 percent below high
The EUR 43.21 quote was 18.41 percent below Fresenius's 52-week high of EUR 52.96 and 23.07 percent above the 52-week low of EUR 35.11 on October 14, 2026. The intraday range was EUR 42.84 to EUR 43.28, with 186,338 shares traded against an average volume of 996,258 shares.
The bid was EUR 43.19 and the ask EUR 43.22 at Lang & Schwarz at 2:01 p.m. CEST. The small spread leaves the stock close to the session high, while the wider annual range places the quote below its upper trading boundary.
Valuation and November 4 date
Fresenius had a market capitalization of EUR 24.3 billion and a price-to-earnings ratio of 15.70 on October 14, 2026. Its trailing dividend yield was 2.00 percent, giving the stock a valuation frame alongside the analyst target.
Fresenius lists November 4, 2026, as the next date for its third-quarter 2026 conference call. The scheduled report gives investors a defined date for comparing the raised full-year 2026 outlook with the next operating update.
Comparison with peers
Fresenius (Xetra, EUR): plus 0.96 percent, P/E 15.70, market capitalization EUR 24.3 billion
Siemens Healthineers (Xetra, EUR): plus 0.35 percent, P/E 20.26, market capitalization EUR 44.8 billion
Fresenius Medical Care (Xetra, EUR): plus 0.16 percent, P/E 11.46, market capitalization EUR 10.1 billion
Price versus October 13 close
Fresenius stock was trading at EUR 43.21 at Lang & Schwarz on October 14, 2026 at 2:01 p.m. CEST, 0.96 percent above the Xetra close of EUR 42.80 on October 13, 2026. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.
Fresenius stock at a glance
- Company: Fresenius SE & Co. KGaA
- ISIN: DE000FRE5EN2
- Ticker: FRE
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 14, 2026, 2:01 p.m. CEST): EUR 43.21
- Change versus Xetra close: plus 0.96 percent
- Xetra close (October 13, 2026): EUR 42.80
- Market capitalization: EUR 24.3 billion (as of October 14, 2026)
- 52-week range: EUR 35.11-EUR 52.96 (as of October 14, 2026)
- Next earnings date: November 4, 2026
Market context: Market report DAX.
